Clinical analysis of 6 cases with sinonasal malignant melanoma.
- Author:
Rongchang MA
;
Yongqiang LI
;
Jianzhe LI
;
Xiaomei LI
- Publication Type:Case Reports
- MeSH:
Combined Modality Therapy;
Humans;
Interferon-alpha;
therapeutic use;
Interleukin-2;
therapeutic use;
Melanoma;
pathology;
therapy;
Paranasal Sinus Neoplasms;
pathology;
therapy;
Retrospective Studies;
Skin Neoplasms;
Survival Rate
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2015;29(9):828-831
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore clinical characteristics of sinonasal malignant melanoma and curative effect of the combined modality therapy.
METHOD:Clinical data of 6 cases with sinonasal malignant melanoma was retrospectively analyzed. All patients received surgery and postoperative radiotherapy. In addition, 3 cases received postoperative chemotherapy which scheme was CDBT and bioimmunotherapy consisted of INF-α and IL-2 after surgery, of which, 2 cases received one cycle of preoperative chemotherapy.
RESULT:Six cases were followed up. The survival time ranged from 15 months to 98 months. The average survival time was 62.7 months. Analyzed by direct method, the 1-year, 3-year and 5-year survival rates were 100%, 83% and 67% respectively. Three cases which received the combined modality therapy, of whch, 2 cases received preoperative chemotherapy have survived by now.
CONCLUSION:The combined modality therapy should be adopted in case of sinonasal malignant melanoma with operation indication. For the patients who can not be operated recently Postbiopsy, it was beneficial to improve the efficacy of therapy that one cycle of preoperative chemotherapy and bioimmunotherapy should be implemented.
